Sulphonamide Scaffold Tuning for Selective MLKL Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanisms of necrosis, particularly necroptosis, are not well understood, and existing compounds do not effectively target the mixed lineage kinase domain-like protein (MLKL) to inhibit this form of cell death, which contributes to various pathological conditions.
Innovation Solution
Development of sulphonamide compounds that selectively inhibit MLKL, offering a new approach to treat necroptosis by targeting this key effector protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used to treat necroptosis, then necroptosis can be inhibited to some extent, but the compounds do not effectively target MLKL and lack selectivity
Solution Approach 1:
The patent modifies chemical parameters of the compounds by changing the core structure from other types to a sulphonamide core, and adjusting substituents at specific positions (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10) to optimize MLKL binding affinity and selectivity while maintaining necroptosis inhibition efficacy
Solution Approach 2:
The patent introduces specific local structural features including a sulphonamide group with particular substitution patterns at defined positions, creating localized chemical characteristics that enhance selective interaction with MLKL while preserving the overall necroptosis inhibition function
2Ease of manufacture
If compounds are designed to target MLKL specifically, then selectivity is improved, but the scope of applicable necroptosis-related conditions remains limited
Solution Approach 1:
The patent designs a universal sulphonamide core structure with variable substituents that can selectively target MLKL across different disease contexts, enabling the same compound framework to address multiple necroptosis-related conditions including neurodegenerative diseases, stroke, coronary heart disease, kidney disease, and AIDS through consistent MLKL inhibition mechanism
Data Source
AI summary
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit MLKL.